The Pharma Letter51m
Samsung Bioepis and Teva link up on Soliris biosimilar in USA
South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...
The Pharma Letter18h
J&J’s Margaret Yu named Artbio CMO
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...
The Pharma Letter23h
Sciwind’s Verdiva Bio deal earnings could top $2.4 billion
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...
The Pharma Letter22h
Vertex out-licenses povetacicept to Zai Lab
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...
The Pharma Letter23h
Positive Phase III results for Pfizer’s sasanlimab
US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...
The Pharma Letter18h
BRIEF—Prefilled syringe presentation of Shingrix accepted for review by FDA
The US Food and Drug Administration (FDA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, GSK’s recombinant zoster vaccine for the prevention of ...